Issue Demand outruns the care pathway, pushing patients into channels of their own

Summary

Jeppe Theisen of Novo Nordisk, which makes GLP-1 treatments, describes a mismatch between demand and access in obesity care. Consumer interest in these drugs is strong, and patients increasingly come to doctors asking for them. Yet he says there are still few clear and effective pathways for obtaining a GLP-1 prescription. As a result, patients are finding routes on their own through new channels. PwC uses the case to show that the surrounding system has not caught up with consumer-led demand, leaving room for providers, pharmacies, and digital health players to build better pathways.